Julia Chambers

Jules has spent over 30 years working internationally, initially with corporates such as Eli Lilly (UK) and Genzyme (US), gaining significant experience in DeepTech commercialisation at the intersection of science, technology and market opportunity.
Jules is established in the NZ early-stage research commercialisation and start-up ecosystem, working with Kiwi start-up’s and the next generation of entrepreneurs. A Return on Science Investment Committee member since 2014, she's also held strategic roles at Callaghan Innovation and Adherium (ASX:ADR); is a Chartered Member of the Institute of Directors NZ and a professional company director.